Forma Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH137978D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

November 2018

Total pages

36

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

Forma Therapeutics Inc (Forma) is a drug discovery and development company that discovers and develops new transformative cancer therapeutics. The company develops technologies to identify the initial molecules that provide drug discovery program. It offers research in the areas of tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions. FORMA's drug development process includes computational and medicinal chemistry, parallel synthesis, X-ray crystallography, and relevant biology studies. The company collaborates with biotechnology companies, pharmaceuticals and biomedicine companies and research institutes for its research and development activities. It operates offices in Watertown and Branford, the US. FORMA is headquartered in Watertown, Massachusetts, the US.

Forma Therapeutics Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Forma Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Forma Therapeutics Raises USD 10 Million In Venture Financing 11

Partnerships 12

Ubiquigent Enters into Development Agreement with Forma Therapeutics 12

Forma Therapeutics Enters into Agreement with Arpeggio Biosciences 13

Celgene Enters into Agreement with Forma Therapeutics 14

ZoBio and Domainex Enter into Agreement with Forma Therapeutics 15

Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 16

Forma Therapeutics Partners With Celgene 17

Forma Therapeutics Enters Into Agreement With Celgene 18

Forma Therapeutics Enters Into Co-Development Agreement With TGen Drug Development 20

FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 21

FORMA Therapeutics Enters Into R&D Agreement With Boehringer Ingelheim 22

Licensing Agreements 23

Forma Therapeutics and HitGen Enter into Licensing Agreement 23

Forma Therapeutics Enters into Licensing Agreement with University of Oxford 24

Forma Therapeutics Enters Into Licensing Agreement With Netherlands Cancer Institute 25

Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 26

Moffitt Cancer Center Enters into Option for Licensing Agreement with Forma Therapeutics 27

Forma Therapeutics Inc-Key Competitors 28

Forma Therapeutics Inc-Key Employees 29

Forma Therapeutics Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Corporate Communications 31

Apr 09, 2018: FORMA Therapeutics Appoints Tim Clackson As Board Director 31

Nov 14, 2017: FORMA Therapeutics Appoints Christine Bellon, Ph.D., J.D., General Counsel and Corporate Secretary 32

Government and Public Interest 33

Feb 21, 2017: FORMA Therapeutics Awarded Grant from Michael J. Fox Foundation for Parkinson's Research 33

Product News 34

Apr 05, 2018: FORMA Therapeutics Achieves Key Objective in Collaboration with Celgene to Advance a Novel Protein Homeostasis Oncology/Immuno-Oncology Program 34

Other Significant Developments 35

Mar 13, 2017: FORMA Therapeutics Announces Achievement of First Clinical Development Milestone in Partnership with Boehringer Ingelheim 35

Appendix 36

Methodology 36

About GlobalData 36

Contact Us 36

Disclaimer 36


List of Figure

List of Figures

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List of Table

List of Tables

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Forma Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Forma Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Forma Therapeutics Raises USD 10 Million In Venture Financing 11

Ubiquigent Enters into Development Agreement with Forma Therapeutics 12

Forma Therapeutics Enters into Agreement with Arpeggio Biosciences 13

Celgene Enters into Agreement with Forma Therapeutics 14

ZoBio and Domainex Enter into Agreement with Forma Therapeutics 15

Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 16

Forma Therapeutics Partners With Celgene 17

Forma Therapeutics Enters Into Agreement With Celgene 18

Forma Therapeutics Enters Into Co-Development Agreement With TGen Drug Development 20

FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 21

FORMA Therapeutics Enters Into R&D Agreement With Boehringer Ingelheim 22

Forma Therapeutics and HitGen Enter into Licensing Agreement 23

Forma Therapeutics Enters into Licensing Agreement with University of Oxford 24

Forma Therapeutics Enters Into Licensing Agreement With Netherlands Cancer Institute 25

Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 26

Moffitt Cancer Center Enters into Option for Licensing Agreement with Forma Therapeutics 27

Forma Therapeutics Inc, Key Competitors 28

Forma Therapeutics Inc, Key Employees 29

Forma Therapeutics Inc, Other Locations 30

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022